Skip to main content
SpringerLink
Log in

Response to “Immune-mediated cholangitis: is it always nivolumab’s fault?”

  • Letter to the Editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

The Original Article was published on 05 April 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61–65. https://doi.org/10.1007/s00262-017-2062-3

    Article  PubMed  Google Scholar 

  2. Gelsomino F, Vitale G, Ardizzoni A (2018) Immune-mediated cholangitis: is it always nivolumab’s fault? Cancer Immunol Immunother https://doi.org/10.1007/s00262-018-2159-3

    Article  PubMed  Google Scholar 

  3. Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672. https://doi.org/10.1093/annonc/mdw649

    Article  PubMed  CAS  Google Scholar 

  4. Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536. https://doi.org/10.1007/s10637-017-0453-0

    Article  CAS  Google Scholar 

  5. Kubo K, Kato M, Mabe K (2017) Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol 15:A35–A36. https://doi.org/10.1016/j.cgh.2017.03.026

    Article  Google Scholar 

  6. Ohara H, Okazaki K, Tsubouchi H et al (2012) Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepato-Biliary-Pancreat Sci 19:536–542. https://doi.org/10.1007/s00534-012-0521-y

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Honkomagome 3-18-22, Bunkyo, Tokyo, 113-8677, Japan

    Jumpei Kashima

  2. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Honkomagome 3-18-22, Bunkyo, Tokyo, 113-8677, Japan

    Yusuke Okuma

Authors
  1. Jumpei Kashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuke Okuma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yusuke Okuma.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

This reply refers to the comment available at doi:https://doi.org/10.1007/s00262-018-2159-3.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kashima, J., Okuma, Y. Response to “Immune-mediated cholangitis: is it always nivolumab’s fault?”. Cancer Immunol Immunother 67, 1329–1330 (2018). https://doi.org/10.1007/s00262-018-2163-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-018-2163-7

Search

Navigation